| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Kidney Glomerulus | 29 | 2019 | 155 | 3.860 |
Why?
|
| Lupus Nephritis | 38 | 2018 | 193 | 3.630 |
Why?
|
| Antibodies, Antinuclear | 36 | 2012 | 171 | 3.590 |
Why?
|
| Autoantibodies | 50 | 2017 | 434 | 3.240 |
Why?
|
| Glomerulonephritis | 17 | 2019 | 77 | 2.410 |
Why?
|
| Lupus Erythematosus, Systemic | 52 | 2018 | 756 | 2.210 |
Why?
|
| Nephritis | 17 | 2015 | 37 | 2.060 |
Why?
|
| Antibodies, Monoclonal | 26 | 2018 | 510 | 2.050 |
Why?
|
| Autoantigens | 12 | 2018 | 91 | 1.960 |
Why?
|
| Collagen Type IV | 5 | 2018 | 28 | 1.690 |
Why?
|
| Anti-Glomerular Basement Membrane Disease | 7 | 2015 | 15 | 1.460 |
Why?
|
| B-Lymphocytes | 22 | 2013 | 329 | 1.350 |
Why?
|
| DNA | 25 | 2012 | 597 | 1.340 |
Why?
|
| Mice | 102 | 2019 | 8472 | 1.280 |
Why?
|
| Autoimmunity | 15 | 2015 | 118 | 1.130 |
Why?
|
| Proteinuria | 14 | 2019 | 136 | 1.100 |
Why?
|
| Dinoprostone | 3 | 2019 | 110 | 1.090 |
Why?
|
| Animals | 124 | 2019 | 20877 | 1.080 |
Why?
|
| Kidney | 23 | 2018 | 945 | 0.940 |
Why?
|
| T-Lymphocytes | 18 | 2013 | 595 | 0.870 |
Why?
|
| Disease Models, Animal | 32 | 2019 | 2550 | 0.790 |
Why?
|
| Autoimmune Diseases | 16 | 2009 | 186 | 0.780 |
Why?
|
| Immunoglobulin G | 22 | 2018 | 481 | 0.760 |
Why?
|
| Immune Tolerance | 8 | 2018 | 114 | 0.750 |
Why?
|
| Cell Nucleus | 6 | 2005 | 305 | 0.690 |
Why?
|
| Epithelial Sodium Channels | 1 | 2019 | 25 | 0.690 |
Why?
|
| Peptides, Cyclic | 1 | 2019 | 35 | 0.680 |
Why?
|
| Immunoconjugates | 6 | 2015 | 26 | 0.670 |
Why?
|
| Protein Kinase C-alpha | 1 | 2018 | 24 | 0.650 |
Why?
|
| Antigen-Antibody Complex | 18 | 2017 | 175 | 0.610 |
Why?
|
| Immunoglobulin Variable Region | 9 | 2009 | 40 | 0.570 |
Why?
|
| Dexamethasone | 2 | 2015 | 150 | 0.570 |
Why?
|
| Mice, Inbred MRL lpr | 20 | 2014 | 118 | 0.540 |
Why?
|
| Mice, Inbred C57BL | 25 | 2018 | 2790 | 0.540 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2018 | 331 | 0.530 |
Why?
|
| Glomerular Basement Membrane | 3 | 2012 | 10 | 0.530 |
Why?
|
| Kidney Failure, Chronic | 2 | 2011 | 365 | 0.520 |
Why?
|
| Lymphocyte Activation | 13 | 2013 | 397 | 0.480 |
Why?
|
| Podocytes | 6 | 2015 | 113 | 0.460 |
Why?
|
| Nephrosis | 1 | 2013 | 6 | 0.460 |
Why?
|
| Macrophages | 8 | 2018 | 647 | 0.460 |
Why?
|
| Antibodies | 9 | 2012 | 241 | 0.450 |
Why?
|
| Antigen-Antibody Reactions | 3 | 2009 | 13 | 0.450 |
Why?
|
| Blood Urea Nitrogen | 4 | 2019 | 65 | 0.450 |
Why?
|
| Signal Transduction | 10 | 2019 | 2688 | 0.430 |
Why?
|
| Plasma Cells | 1 | 2012 | 19 | 0.420 |
Why?
|
| Tumor Necrosis Factor-alpha | 4 | 2019 | 626 | 0.410 |
Why?
|
| Immunoglobulin Idiotypes | 9 | 1999 | 16 | 0.400 |
Why?
|
| Genes, Immunoglobulin | 5 | 2000 | 56 | 0.390 |
Why?
|
| Nephritis, Interstitial | 5 | 2005 | 14 | 0.390 |
Why?
|
| Chemokines | 2 | 2018 | 119 | 0.390 |
Why?
|
| Humans | 69 | 2021 | 68525 | 0.380 |
Why?
|
| Biomedical Research | 3 | 2018 | 310 | 0.380 |
Why?
|
| Deoxyribonuclease I | 4 | 1997 | 16 | 0.370 |
Why?
|
| Cell Survival | 1 | 2013 | 901 | 0.360 |
Why?
|
| Female | 44 | 2019 | 38015 | 0.360 |
Why?
|
| Apoptosis | 5 | 2018 | 1640 | 0.350 |
Why?
|
| DNA Methylation | 1 | 2011 | 192 | 0.350 |
Why?
|
| Epigenesis, Genetic | 1 | 2011 | 163 | 0.350 |
Why?
|
| Severity of Illness Index | 7 | 2015 | 1851 | 0.340 |
Why?
|
| Models, Chemical | 1 | 2009 | 155 | 0.330 |
Why?
|
| T-Lymphocyte Subsets | 9 | 2015 | 126 | 0.320 |
Why?
|
| Mice, Mutant Strains | 15 | 2010 | 166 | 0.320 |
Why?
|
| Mice, Knockout | 19 | 2018 | 1692 | 0.310 |
Why?
|
| Research Personnel | 2 | 2018 | 83 | 0.310 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2011 | 785 | 0.310 |
Why?
|
| Interferon-alpha | 4 | 2012 | 46 | 0.310 |
Why?
|
| Collagen | 3 | 2000 | 636 | 0.300 |
Why?
|
| Drug Delivery Systems | 3 | 2018 | 236 | 0.300 |
Why?
|
| Cell Line | 6 | 2019 | 1752 | 0.300 |
Why?
|
| Kidney Transplantation | 5 | 2002 | 839 | 0.290 |
Why?
|
| Hybridomas | 7 | 2018 | 25 | 0.290 |
Why?
|
| Nephrotic Syndrome | 3 | 2005 | 61 | 0.290 |
Why?
|
| Mitochondria | 4 | 2018 | 643 | 0.280 |
Why?
|
| Immunoglobulin Heavy Chains | 5 | 2002 | 72 | 0.280 |
Why?
|
| Lymphoproliferative Disorders | 4 | 1996 | 37 | 0.280 |
Why?
|
| Kidney Tubules | 3 | 2005 | 80 | 0.280 |
Why?
|
| Catheter-Related Infections | 3 | 2015 | 43 | 0.280 |
Why?
|
| Simvastatin | 1 | 2006 | 34 | 0.280 |
Why?
|
| Mice, Inbred Strains | 11 | 2009 | 181 | 0.270 |
Why?
|
| Caveolae | 1 | 2005 | 3 | 0.260 |
Why?
|
| Caveolins | 1 | 2005 | 6 | 0.260 |
Why?
|
| Kidney Diseases | 8 | 2005 | 307 | 0.260 |
Why?
|
| Mice, Inbred BALB C | 13 | 2014 | 532 | 0.260 |
Why?
|
| Receptors, IgG | 3 | 2018 | 94 | 0.260 |
Why?
|
| Mice, Transgenic | 11 | 2009 | 1032 | 0.260 |
Why?
|
| Diabetes Mellitus | 1 | 2011 | 693 | 0.250 |
Why?
|
| Physicians | 2 | 2018 | 324 | 0.250 |
Why?
|
| Epitopes | 4 | 2009 | 146 | 0.250 |
Why?
|
| Binding Sites, Antibody | 7 | 1989 | 34 | 0.250 |
Why?
|
| Spleen | 13 | 2012 | 301 | 0.240 |
Why?
|
| Endothelial Cells | 3 | 2019 | 384 | 0.240 |
Why?
|
| Thymus Gland | 2 | 2002 | 97 | 0.240 |
Why?
|
| Intensive Care Units | 3 | 2015 | 344 | 0.240 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2006 | 212 | 0.240 |
Why?
|
| Molecular Sequence Data | 14 | 2013 | 1446 | 0.240 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2005 | 231 | 0.230 |
Why?
|
| Gene Expression Regulation | 4 | 2018 | 1293 | 0.230 |
Why?
|
| Antibody Specificity | 10 | 2003 | 98 | 0.220 |
Why?
|
| B-Cell Activating Factor | 4 | 2011 | 12 | 0.220 |
Why?
|
| Myosins | 2 | 2005 | 34 | 0.220 |
Why?
|
| Immune Complex Diseases | 6 | 2006 | 10 | 0.210 |
Why?
|
| DNA, Single-Stranded | 4 | 1995 | 41 | 0.210 |
Why?
|
| Amino Acid Sequence | 11 | 2004 | 1082 | 0.200 |
Why?
|
| Laminin | 2 | 1993 | 62 | 0.200 |
Why?
|
| Immunocompromised Host | 1 | 2021 | 55 | 0.200 |
Why?
|
| Nephritis, Hereditary | 2 | 2000 | 8 | 0.200 |
Why?
|
| Sheep | 4 | 2018 | 128 | 0.190 |
Why?
|
| Protein Structure, Tertiary | 2 | 2013 | 322 | 0.190 |
Why?
|
| Epitopes, T-Lymphocyte | 1 | 2000 | 38 | 0.190 |
Why?
|
| Injections, Intraperitoneal | 2 | 2019 | 89 | 0.190 |
Why?
|
| Graft vs Host Disease | 5 | 2017 | 163 | 0.180 |
Why?
|
| Cytoplasm | 2 | 2005 | 155 | 0.180 |
Why?
|
| DNA-Binding Proteins | 4 | 2014 | 700 | 0.180 |
Why?
|
| Biopsy | 4 | 2015 | 539 | 0.180 |
Why?
|
| Immunoglobulin Fragments | 2 | 2018 | 14 | 0.180 |
Why?
|
| Carrier Proteins | 2 | 2018 | 597 | 0.180 |
Why?
|
| Education, Medical, Graduate | 2 | 2018 | 214 | 0.170 |
Why?
|
| Primary Cell Culture | 1 | 2019 | 56 | 0.170 |
Why?
|
| CD4 Antigens | 4 | 2003 | 42 | 0.170 |
Why?
|
| Mitochondrial Proteins | 2 | 2013 | 113 | 0.170 |
Why?
|
| Complementarity Determining Regions | 1 | 1998 | 4 | 0.170 |
Why?
|
| Receptors, CCR | 1 | 2018 | 1 | 0.170 |
Why?
|
| Antiphospholipid Syndrome | 3 | 2009 | 25 | 0.170 |
Why?
|
| Temperature | 2 | 2004 | 340 | 0.170 |
Why?
|
| Patch-Clamp Techniques | 1 | 2019 | 204 | 0.170 |
Why?
|
| Immune Sera | 1 | 2018 | 30 | 0.160 |
Why?
|
| Cyclophosphamide | 2 | 2003 | 129 | 0.160 |
Why?
|
| Flow Cytometry | 6 | 2010 | 489 | 0.160 |
Why?
|
| Cells, Cultured | 7 | 2015 | 2673 | 0.160 |
Why?
|
| Oxidative Phosphorylation | 1 | 2018 | 54 | 0.160 |
Why?
|
| Education | 1 | 2018 | 83 | 0.160 |
Why?
|
| Organizational Innovation | 2 | 2015 | 55 | 0.160 |
Why?
|
| Inflammation | 4 | 2015 | 1030 | 0.160 |
Why?
|
| Th17 Cells | 1 | 2019 | 116 | 0.160 |
Why?
|
| Amino Acids | 2 | 2015 | 131 | 0.160 |
Why?
|
| Receptors, Aryl Hydrocarbon | 1 | 2018 | 46 | 0.160 |
Why?
|
| Aging | 3 | 2018 | 911 | 0.160 |
Why?
|
| Binding Sites | 4 | 2009 | 631 | 0.150 |
Why?
|
| Liver Transplantation | 1 | 2021 | 400 | 0.150 |
Why?
|
| Germinal Center | 2 | 2012 | 13 | 0.150 |
Why?
|
| Homeodomain Proteins | 2 | 2003 | 157 | 0.150 |
Why?
|
| Estrogen Receptor alpha | 1 | 2017 | 65 | 0.150 |
Why?
|
| Biomarkers | 3 | 2013 | 1593 | 0.150 |
Why?
|
| Education, Medical | 1 | 2018 | 147 | 0.150 |
Why?
|
| Nitric Oxide | 1 | 2019 | 382 | 0.150 |
Why?
|
| Tyrosine | 2 | 2005 | 196 | 0.150 |
Why?
|
| Rabbits | 8 | 2006 | 509 | 0.140 |
Why?
|
| Base Sequence | 8 | 2004 | 1015 | 0.140 |
Why?
|
| ErbB Receptors | 1 | 2018 | 239 | 0.140 |
Why?
|
| Antigens, Surface | 3 | 1999 | 71 | 0.140 |
Why?
|
| Membrane Glycoproteins | 4 | 2009 | 370 | 0.140 |
Why?
|
| Serologic Tests | 2 | 2010 | 46 | 0.140 |
Why?
|
| Societies, Medical | 1 | 2018 | 403 | 0.140 |
Why?
|
| Receptors, Cell Surface | 1 | 1997 | 248 | 0.140 |
Why?
|
| Interleukin-23 | 1 | 2015 | 13 | 0.140 |
Why?
|
| Autophagy | 2 | 2015 | 207 | 0.140 |
Why?
|
| Energy Metabolism | 1 | 2017 | 222 | 0.140 |
Why?
|
| Communication | 2 | 2015 | 329 | 0.140 |
Why?
|
| Indoles | 2 | 2009 | 146 | 0.140 |
Why?
|
| Mice, Inbred CBA | 5 | 2004 | 107 | 0.140 |
Why?
|
| Disease Progression | 5 | 2017 | 1037 | 0.130 |
Why?
|
| Leptin | 1 | 2015 | 80 | 0.130 |
Why?
|
| Gene Expression | 6 | 2017 | 770 | 0.130 |
Why?
|
| B-Lymphocyte Subsets | 4 | 2006 | 25 | 0.130 |
Why?
|
| Mice, Inbred NZB | 7 | 2011 | 37 | 0.130 |
Why?
|
| Knowledge Management | 1 | 2015 | 2 | 0.130 |
Why?
|
| Recombinant Fusion Proteins | 4 | 2011 | 376 | 0.130 |
Why?
|
| Immunohistochemistry | 3 | 2013 | 1174 | 0.130 |
Why?
|
| Crosses, Genetic | 4 | 2011 | 60 | 0.130 |
Why?
|
| CD55 Antigens | 2 | 2006 | 13 | 0.130 |
Why?
|
| Male | 24 | 2021 | 37281 | 0.130 |
Why?
|
| Lymphocyte Cooperation | 3 | 2003 | 5 | 0.130 |
Why?
|
| Nephrology | 2 | 2008 | 43 | 0.130 |
Why?
|
| Infection Control | 1 | 2015 | 101 | 0.130 |
Why?
|
| Annexin A1 | 1 | 2014 | 1 | 0.130 |
Why?
|
| Antigen Presentation | 1 | 1994 | 76 | 0.120 |
Why?
|
| Receptors, Antigen, T-Cell, alpha-beta | 4 | 1998 | 29 | 0.120 |
Why?
|
| Phosphopyruvate Hydratase | 1 | 2014 | 35 | 0.120 |
Why?
|
| rab4 GTP-Binding Proteins | 1 | 2013 | 2 | 0.120 |
Why?
|
| Sialic Acids | 1 | 2013 | 27 | 0.120 |
Why?
|
| Hepatocytes | 1 | 2015 | 205 | 0.120 |
Why?
|
| Antigens | 3 | 1999 | 90 | 0.120 |
Why?
|
| Immunity, Innate | 2 | 2011 | 156 | 0.120 |
Why?
|
| Acute Disease | 3 | 2006 | 658 | 0.120 |
Why?
|
| GTP Phosphohydrolases | 1 | 2013 | 46 | 0.120 |
Why?
|
| Puromycin | 1 | 2013 | 3 | 0.120 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2015 | 234 | 0.120 |
Why?
|
| Interdisciplinary Communication | 1 | 2014 | 93 | 0.120 |
Why?
|
| Toll-Like Receptor 9 | 2 | 2018 | 12 | 0.120 |
Why?
|
| Synaptophysin | 1 | 2013 | 16 | 0.110 |
Why?
|
| Germ-Free Life | 2 | 2005 | 12 | 0.110 |
Why?
|
| Cytokines | 6 | 2015 | 866 | 0.110 |
Why?
|
| Glomerulonephritis, Membranous | 1 | 1992 | 8 | 0.110 |
Why?
|
| Antibodies, Anti-Idiotypic | 3 | 1999 | 43 | 0.110 |
Why?
|
| Lupus Vulgaris | 3 | 1999 | 5 | 0.110 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2014 | 194 | 0.110 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2013 | 114 | 0.110 |
Why?
|
| CD59 Antigens | 1 | 2012 | 30 | 0.110 |
Why?
|
| Phenotype | 8 | 2010 | 946 | 0.110 |
Why?
|
| Rats | 11 | 2005 | 5300 | 0.100 |
Why?
|
| Immunosuppressive Agents | 4 | 2021 | 514 | 0.100 |
Why?
|
| Lymphokines | 1 | 1991 | 49 | 0.100 |
Why?
|
| Guideline Adherence | 1 | 2014 | 284 | 0.100 |
Why?
|
| Immunoglobulin M | 7 | 2013 | 172 | 0.100 |
Why?
|
| Middle Aged | 9 | 2021 | 21119 | 0.100 |
Why?
|
| Ribonucleoproteins, Small Nuclear | 1 | 1990 | 11 | 0.100 |
Why?
|
| Evidence-Based Medicine | 1 | 2014 | 438 | 0.100 |
Why?
|
| Feasibility Studies | 1 | 2013 | 652 | 0.100 |
Why?
|
| Macrophage Activation | 2 | 2008 | 75 | 0.100 |
Why?
|
| Time Factors | 4 | 2013 | 4655 | 0.100 |
Why?
|
| Genetic Markers | 1 | 2011 | 144 | 0.100 |
Why?
|
| Chromatin | 2 | 2007 | 76 | 0.090 |
Why?
|
| Biomarkers, Tumor | 1 | 2014 | 508 | 0.090 |
Why?
|
| Abatacept | 5 | 2011 | 17 | 0.090 |
Why?
|
| Kinetics | 3 | 2000 | 1047 | 0.090 |
Why?
|
| Disease Susceptibility | 2 | 2017 | 179 | 0.090 |
Why?
|
| Poly(ADP-ribose) Polymerases | 1 | 2009 | 39 | 0.090 |
Why?
|
| Microscopy, Electron | 6 | 2004 | 351 | 0.090 |
Why?
|
| Protein Structure, Secondary | 1 | 2009 | 136 | 0.090 |
Why?
|
| Cross-Linking Reagents | 1 | 2009 | 80 | 0.090 |
Why?
|
| Antibody Affinity | 2 | 2000 | 26 | 0.090 |
Why?
|
| Toll-Like Receptor 7 | 1 | 2009 | 17 | 0.090 |
Why?
|
| Predictive Value of Tests | 1 | 2013 | 1465 | 0.090 |
Why?
|
| Adult | 8 | 2014 | 21375 | 0.080 |
Why?
|
| Anticarcinogenic Agents | 1 | 2009 | 52 | 0.080 |
Why?
|
| CD79 Antigens | 1 | 2008 | 5 | 0.080 |
Why?
|
| Lymphocyte Depletion | 1 | 2008 | 34 | 0.080 |
Why?
|
| Necrosis | 1 | 2009 | 239 | 0.080 |
Why?
|
| Microscopy, Immunoelectron | 2 | 2005 | 27 | 0.080 |
Why?
|
| Aged | 7 | 2013 | 14842 | 0.080 |
Why?
|
| Immunotherapy | 1 | 2010 | 212 | 0.080 |
Why?
|
| Receptors, Antigen, B-Cell | 2 | 1999 | 89 | 0.080 |
Why?
|
| Antilymphocyte Serum | 1 | 1988 | 52 | 0.080 |
Why?
|
| Major Histocompatibility Complex | 1 | 1988 | 34 | 0.080 |
Why?
|
| Mice, Inbred DBA | 4 | 2000 | 120 | 0.080 |
Why?
|
| DNA Fragmentation | 1 | 2007 | 85 | 0.080 |
Why?
|
| Rheumatology | 1 | 2008 | 46 | 0.080 |
Why?
|
| Treatment Outcome | 2 | 2018 | 7028 | 0.080 |
Why?
|
| Vascular Endothelial Growth Factor A | 2 | 2006 | 219 | 0.080 |
Why?
|
| Glomerulonephritis, IGA | 1 | 2007 | 12 | 0.080 |
Why?
|
| Basement Membrane | 5 | 1997 | 48 | 0.080 |
Why?
|
| Thrombocytopenia | 1 | 1988 | 122 | 0.080 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2011 | 1745 | 0.080 |
Why?
|
| Complement System Proteins | 5 | 2001 | 135 | 0.080 |
Why?
|
| Glomerular Filtration Rate | 2 | 2001 | 274 | 0.070 |
Why?
|
| Myeloid Progenitor Cells | 1 | 2006 | 9 | 0.070 |
Why?
|
| CD40 Antigens | 2 | 1997 | 9 | 0.070 |
Why?
|
| Cell Proliferation | 2 | 2013 | 1173 | 0.070 |
Why?
|
| Adjuvants, Immunologic | 2 | 2004 | 63 | 0.070 |
Why?
|
| Cross Reactions | 4 | 1990 | 57 | 0.070 |
Why?
|
| Interleukin-2 | 3 | 2003 | 133 | 0.070 |
Why?
|
| Receptors, Fc | 1 | 2006 | 19 | 0.070 |
Why?
|
| fas Receptor | 2 | 2003 | 54 | 0.070 |
Why?
|
| Receptors, Complement | 1 | 2006 | 58 | 0.070 |
Why?
|
| Mevalonic Acid | 1 | 2006 | 27 | 0.070 |
Why?
|
| Immunophenotyping | 4 | 2015 | 110 | 0.070 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 1 | 2006 | 95 | 0.070 |
Why?
|
| Up-Regulation | 2 | 2006 | 682 | 0.070 |
Why?
|
| Capillaries | 1 | 1986 | 105 | 0.070 |
Why?
|
| Indoleamine-Pyrrole 2,3,-Dioxygenase | 2 | 2015 | 10 | 0.070 |
Why?
|
| Sex Factors | 3 | 2017 | 1265 | 0.070 |
Why?
|
| Sequence Homology, Amino Acid | 2 | 1997 | 230 | 0.070 |
Why?
|
| Tumor Cells, Cultured | 2 | 1997 | 852 | 0.070 |
Why?
|
| Nuclear Pore | 1 | 2005 | 2 | 0.070 |
Why?
|
| Jurkat Cells | 2 | 2013 | 59 | 0.070 |
Why?
|
| Chromosomes | 1 | 2005 | 17 | 0.070 |
Why?
|
| Phosphoproteins | 3 | 2005 | 202 | 0.070 |
Why?
|
| Complement Activation | 1 | 2006 | 145 | 0.060 |
Why?
|
| Young Adult | 2 | 2014 | 5708 | 0.060 |
Why?
|
| Nitric Oxide Synthase Type II | 1 | 2005 | 201 | 0.060 |
Why?
|
| Binding, Competitive | 3 | 1998 | 165 | 0.060 |
Why?
|
| Heat-Shock Proteins | 2 | 1995 | 69 | 0.060 |
Why?
|
| Dimethylallyltranstransferase | 1 | 2004 | 2 | 0.060 |
Why?
|
| Neutrophils | 2 | 2003 | 204 | 0.060 |
Why?
|
| United States | 4 | 2018 | 7335 | 0.060 |
Why?
|
| Antigens, Polyomavirus Transforming | 1 | 2004 | 15 | 0.060 |
Why?
|
| Platelet Endothelial Cell Adhesion Molecule-1 | 1 | 2004 | 29 | 0.060 |
Why?
|
| Caveolin 1 | 1 | 2005 | 59 | 0.060 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 5 | 2011 | 507 | 0.060 |
Why?
|
| MAP Kinase Signaling System | 1 | 2005 | 247 | 0.060 |
Why?
|
| Adolescent | 3 | 2014 | 8903 | 0.060 |
Why?
|
| Cell Separation | 1 | 2004 | 132 | 0.060 |
Why?
|
| Transgenes | 2 | 2002 | 92 | 0.060 |
Why?
|
| Evidence-Based Practice | 2 | 2015 | 146 | 0.060 |
Why?
|
| Adenosine Triphosphate | 1 | 2005 | 314 | 0.060 |
Why?
|
| Mice, Inbred AKR | 2 | 1993 | 8 | 0.060 |
Why?
|
| Diagnosis, Differential | 3 | 2001 | 1139 | 0.060 |
Why?
|
| Remission Induction | 3 | 2010 | 111 | 0.060 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2004 | 214 | 0.060 |
Why?
|
| Epithelial Cells | 1 | 2005 | 431 | 0.060 |
Why?
|
| Bacterial Proteins | 2 | 1995 | 244 | 0.060 |
Why?
|
| Transplantation, Isogeneic | 1 | 2002 | 19 | 0.060 |
Why?
|
| Child | 2 | 2013 | 6400 | 0.060 |
Why?
|
| Prospective Studies | 3 | 2015 | 3702 | 0.060 |
Why?
|
| Academic Medical Centers | 2 | 2015 | 281 | 0.050 |
Why?
|
| Membrane Proteins | 2 | 2004 | 617 | 0.050 |
Why?
|
| Complement C3 | 5 | 2012 | 101 | 0.050 |
Why?
|
| Microvilli | 2 | 1997 | 22 | 0.050 |
Why?
|
| Interleukin-10 | 1 | 2002 | 144 | 0.050 |
Why?
|
| Lipoproteins, LDL | 1 | 2004 | 343 | 0.050 |
Why?
|
| Animals, Newborn | 1 | 2002 | 396 | 0.050 |
Why?
|
| Antioxidants | 1 | 2003 | 304 | 0.050 |
Why?
|
| Iodine Radioisotopes | 3 | 1988 | 119 | 0.050 |
Why?
|
| Gene Expression Profiling | 2 | 2017 | 498 | 0.050 |
Why?
|
| Mutation | 2 | 2004 | 1213 | 0.050 |
Why?
|
| Mycophenolic Acid | 1 | 2021 | 62 | 0.050 |
Why?
|
| Immunization | 2 | 2006 | 86 | 0.050 |
Why?
|
| Dietary Supplements | 1 | 2003 | 331 | 0.050 |
Why?
|
| Dose-Response Relationship, Immunologic | 1 | 2000 | 31 | 0.050 |
Why?
|
| Immunoglobulin kappa-Chains | 2 | 1991 | 30 | 0.050 |
Why?
|
| Nucleosomes | 1 | 2000 | 25 | 0.050 |
Why?
|
| Clonal Anergy | 1 | 2000 | 4 | 0.050 |
Why?
|
| Isoelectric Focusing | 3 | 1990 | 42 | 0.050 |
Why?
|
| Genes, bcl-2 | 1 | 2000 | 10 | 0.050 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 2 | 2018 | 216 | 0.050 |
Why?
|
| Phylogeny | 1 | 2021 | 196 | 0.050 |
Why?
|
| Recombinant Proteins | 2 | 2002 | 742 | 0.050 |
Why?
|
| Biosensing Techniques | 1 | 2000 | 51 | 0.050 |
Why?
|
| Cell Line, Tumor | 1 | 2005 | 1849 | 0.050 |
Why?
|
| Phosphotyrosine | 1 | 1999 | 41 | 0.050 |
Why?
|
| Multifactorial Inheritance | 1 | 1999 | 10 | 0.050 |
Why?
|
| Clone Cells | 2 | 1991 | 67 | 0.050 |
Why?
|
| Tacrolimus | 1 | 2021 | 127 | 0.050 |
Why?
|
| Viral Fusion Proteins | 1 | 1999 | 4 | 0.040 |
Why?
|
| Capsid | 1 | 1999 | 8 | 0.040 |
Why?
|
| Bacteriophage M13 | 1 | 1999 | 12 | 0.040 |
Why?
|
| Environment, Controlled | 1 | 1999 | 9 | 0.040 |
Why?
|
| Adenoviridae | 2 | 2011 | 295 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2000 | 174 | 0.040 |
Why?
|
| Cattle | 1 | 2000 | 475 | 0.040 |
Why?
|
| Sensitivity and Specificity | 1 | 2003 | 1753 | 0.040 |
Why?
|
| Oxidative Stress | 1 | 2003 | 718 | 0.040 |
Why?
|
| Mice, SCID | 2 | 2014 | 238 | 0.040 |
Why?
|
| Down-Regulation | 3 | 2006 | 447 | 0.040 |
Why?
|
| Charities | 1 | 2018 | 3 | 0.040 |
Why?
|
| Statistics, Nonparametric | 2 | 2011 | 306 | 0.040 |
Why?
|
| Foundations | 1 | 2018 | 17 | 0.040 |
Why?
|
| Immunoglobulin alpha-Chains | 1 | 1998 | 3 | 0.040 |
Why?
|
| Training Support | 1 | 2018 | 17 | 0.040 |
Why?
|
| Biological Transport, Active | 1 | 1998 | 49 | 0.040 |
Why?
|
| Awards and Prizes | 1 | 2018 | 27 | 0.040 |
Why?
|
| Enalapril | 2 | 1991 | 86 | 0.040 |
Why?
|
| Cellular Microenvironment | 1 | 2018 | 10 | 0.040 |
Why?
|
| Lipopolysaccharides | 2 | 2013 | 455 | 0.040 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2018 | 109 | 0.040 |
Why?
|
| Phosphorylation | 2 | 2005 | 1199 | 0.040 |
Why?
|
| Chaperonins | 2 | 1995 | 4 | 0.040 |
Why?
|
| Consensus Development Conferences as Topic | 1 | 2018 | 12 | 0.040 |
Why?
|
| Prognosis | 1 | 2003 | 2093 | 0.040 |
Why?
|
| Apolipoprotein A-I | 1 | 1998 | 29 | 0.040 |
Why?
|
| Heparin-binding EGF-like Growth Factor | 1 | 2018 | 17 | 0.040 |
Why?
|
| Referral and Consultation | 1 | 2001 | 383 | 0.040 |
Why?
|
| Vaccines, DNA | 1 | 1998 | 9 | 0.040 |
Why?
|
| Career Choice | 1 | 2018 | 98 | 0.040 |
Why?
|
| Immediate-Early Proteins | 1 | 1998 | 63 | 0.040 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2011 | 710 | 0.040 |
Why?
|
| Granulomatosis with Polyangiitis | 1 | 1997 | 11 | 0.040 |
Why?
|
| HSP70 Heat-Shock Proteins | 2 | 1995 | 42 | 0.040 |
Why?
|
| Research Support as Topic | 1 | 2018 | 58 | 0.040 |
Why?
|
| Liver Neoplasms, Experimental | 1 | 1997 | 38 | 0.040 |
Why?
|
| CD40 Ligand | 3 | 2008 | 14 | 0.040 |
Why?
|
| Age Factors | 1 | 2002 | 1860 | 0.040 |
Why?
|
| Observer Variation | 2 | 2008 | 330 | 0.040 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2009 | 536 | 0.040 |
Why?
|
| Sequence Analysis | 1 | 1997 | 12 | 0.040 |
Why?
|
| Mentoring | 1 | 2018 | 53 | 0.040 |
Why?
|
| Gene Regulatory Networks | 1 | 2017 | 94 | 0.040 |
Why?
|
| Sequence Alignment | 1 | 1997 | 165 | 0.040 |
Why?
|
| Receptors, Antigen, T-Cell, gamma-delta | 1 | 1996 | 8 | 0.040 |
Why?
|
| Sequence Homology, Nucleic Acid | 2 | 1994 | 95 | 0.040 |
Why?
|
| Endocytosis | 1 | 1997 | 113 | 0.040 |
Why?
|
| Glomerular Mesangium | 1 | 1997 | 53 | 0.040 |
Why?
|
| Biological Transport | 1 | 1997 | 210 | 0.040 |
Why?
|
| Protein Conformation | 1 | 1998 | 362 | 0.040 |
Why?
|
| Lipid Metabolism | 1 | 2017 | 186 | 0.040 |
Why?
|
| Immunoglobulin Class Switching | 1 | 1996 | 12 | 0.040 |
Why?
|
| Interferon-gamma | 2 | 2002 | 241 | 0.040 |
Why?
|
| Lymphopenia | 3 | 2003 | 12 | 0.040 |
Why?
|
| Cloning, Molecular | 1 | 1997 | 357 | 0.040 |
Why?
|
| Students, Medical | 1 | 2018 | 210 | 0.040 |
Why?
|
| CD4-Positive T-Lymphocytes | 3 | 2003 | 226 | 0.040 |
Why?
|
| Fluorescent Antibody Technique | 3 | 1987 | 282 | 0.040 |
Why?
|
| Lymphocyte Specific Protein Tyrosine Kinase p56(lck) | 1 | 1996 | 3 | 0.040 |
Why?
|
| Rats, Inbred Lew | 3 | 1986 | 150 | 0.040 |
Why?
|
| Computational Biology | 1 | 2017 | 190 | 0.030 |
Why?
|
| Concanavalin A | 1 | 1996 | 22 | 0.030 |
Why?
|
| Survival Rate | 2 | 2009 | 1055 | 0.030 |
Why?
|
| Drug Therapy, Combination | 2 | 2011 | 648 | 0.030 |
Why?
|
| Quinazolinones | 1 | 2015 | 7 | 0.030 |
Why?
|
| Macrophages, Peritoneal | 1 | 2015 | 67 | 0.030 |
Why?
|
| CD8 Antigens | 3 | 2003 | 25 | 0.030 |
Why?
|
| src-Family Kinases | 1 | 1996 | 91 | 0.030 |
Why?
|
| Chemokine CCL2 | 1 | 2015 | 101 | 0.030 |
Why?
|
| Antibody Formation | 2 | 1988 | 93 | 0.030 |
Why?
|
| Piperidines | 1 | 2015 | 123 | 0.030 |
Why?
|
| Myeloid Cells | 1 | 2015 | 57 | 0.030 |
Why?
|
| Vasculitis | 3 | 2003 | 33 | 0.030 |
Why?
|
| Collagenases | 1 | 1994 | 34 | 0.030 |
Why?
|
| Bacterial Toxins | 1 | 1994 | 50 | 0.030 |
Why?
|
| Acute Kidney Injury | 1 | 1997 | 232 | 0.030 |
Why?
|
| Antigen-Presenting Cells | 3 | 1999 | 50 | 0.030 |
Why?
|
| Immunoglobulin Light Chains | 1 | 1994 | 19 | 0.030 |
Why?
|
| Role | 1 | 2014 | 25 | 0.030 |
Why?
|
| Albuminuria | 1 | 1995 | 171 | 0.030 |
Why?
|
| Endothelium, Vascular | 1 | 1996 | 371 | 0.030 |
Why?
|
| Mice, Congenic | 2 | 2003 | 13 | 0.030 |
Why?
|
| Skin | 2 | 2012 | 451 | 0.030 |
Why?
|
| Carbohydrate Conformation | 1 | 2013 | 25 | 0.030 |
Why?
|
| Carbohydrate Sequence | 1 | 2013 | 45 | 0.030 |
Why?
|
| Chronic Disease | 3 | 2006 | 1329 | 0.030 |
Why?
|
| Dynamins | 1 | 2013 | 14 | 0.030 |
Why?
|
| Transcription Factors | 1 | 1998 | 753 | 0.030 |
Why?
|
| Capillary Permeability | 2 | 1984 | 69 | 0.030 |
Why?
|
| Curriculum | 1 | 2018 | 575 | 0.030 |
Why?
|
| Bone Marrow Cells | 2 | 2006 | 217 | 0.030 |
Why?
|
| Catheters, Indwelling | 1 | 2014 | 72 | 0.030 |
Why?
|
| Stress, Physiological | 1 | 2015 | 215 | 0.030 |
Why?
|
| Feedback, Physiological | 1 | 2013 | 38 | 0.030 |
Why?
|
| Cardiolipins | 2 | 2008 | 12 | 0.030 |
Why?
|
| Enzyme Activation | 1 | 2015 | 791 | 0.030 |
Why?
|
| Risk Factors | 1 | 2003 | 5719 | 0.030 |
Why?
|
| Diphosphonates | 1 | 2013 | 39 | 0.030 |
Why?
|
| Hemoglobinuria | 1 | 2012 | 2 | 0.030 |
Why?
|
| Complement C5 | 1 | 2012 | 3 | 0.030 |
Why?
|
| Glycosylation | 1 | 2013 | 185 | 0.030 |
Why?
|
| Adenocarcinoma | 1 | 1996 | 475 | 0.030 |
Why?
|
| Rheumatoid Factor | 2 | 2006 | 21 | 0.030 |
Why?
|
| Anemia, Hemolytic | 1 | 2012 | 37 | 0.030 |
Why?
|
| Protein Binding | 1 | 1996 | 1027 | 0.030 |
Why?
|
| Cell Membrane | 1 | 1994 | 523 | 0.030 |
Why?
|
| Lysosomes | 1 | 2013 | 136 | 0.030 |
Why?
|
| Quality Assurance, Health Care | 1 | 2014 | 177 | 0.030 |
Why?
|
| Blotting, Western | 2 | 1994 | 954 | 0.030 |
Why?
|
| Molecular Targeted Therapy | 1 | 2013 | 170 | 0.030 |
Why?
|
| Dermatitis | 1 | 2012 | 28 | 0.030 |
Why?
|
| Polymerase Chain Reaction | 1 | 1993 | 492 | 0.030 |
Why?
|
| Immunoglobulin Fab Fragments | 1 | 1992 | 48 | 0.030 |
Why?
|
| Statistics as Topic | 1 | 1992 | 219 | 0.030 |
Why?
|
| Proteomics | 1 | 2014 | 246 | 0.030 |
Why?
|
| Internship and Residency | 1 | 2018 | 596 | 0.030 |
Why?
|
| Homeostasis | 1 | 2013 | 291 | 0.030 |
Why?
|
| Immunoglobulin Isotypes | 1 | 1991 | 28 | 0.030 |
Why?
|
| Histocompatibility Antigens | 1 | 1991 | 12 | 0.030 |
Why?
|
| Models, Molecular | 1 | 1994 | 546 | 0.030 |
Why?
|
| Lac Operon | 1 | 2011 | 54 | 0.030 |
Why?
|
| Gene Rearrangement, B-Lymphocyte, Heavy Chain | 2 | 2002 | 8 | 0.030 |
Why?
|
| Interleukin-4 | 1 | 1991 | 69 | 0.030 |
Why?
|
| Peptides | 1 | 1994 | 455 | 0.030 |
Why?
|
| Pyridines | 1 | 2013 | 261 | 0.030 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2013 | 284 | 0.020 |
Why?
|
| snRNP Core Proteins | 1 | 1990 | 5 | 0.020 |
Why?
|
| Ribonucleoproteins | 1 | 1990 | 19 | 0.020 |
Why?
|
| Immunotherapy, Adoptive | 1 | 1992 | 131 | 0.020 |
Why?
|
| Microscopy, Fluorescence | 1 | 1992 | 261 | 0.020 |
Why?
|
| Dependovirus | 1 | 2011 | 34 | 0.020 |
Why?
|
| Adaptive Immunity | 1 | 2011 | 37 | 0.020 |
Why?
|
| Contraindications | 1 | 1990 | 52 | 0.020 |
Why?
|
| Cell Differentiation | 2 | 2009 | 1034 | 0.020 |
Why?
|
| Cell Movement | 2 | 2003 | 630 | 0.020 |
Why?
|
| Specimen Handling | 1 | 1990 | 46 | 0.020 |
Why?
|
| Myocardium | 2 | 2008 | 1204 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 2018 | 2798 | 0.020 |
Why?
|
| Genetic Vectors | 2 | 2003 | 311 | 0.020 |
Why?
|
| Anemia | 1 | 1991 | 104 | 0.020 |
Why?
|
| Polymorphism, Restriction Fragment Length | 1 | 1989 | 44 | 0.020 |
Why?
|
| Quality Improvement | 1 | 2014 | 413 | 0.020 |
Why?
|
| Nephrectomy | 1 | 1990 | 103 | 0.020 |
Why?
|
| Heparin | 1 | 1990 | 205 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2013 | 1548 | 0.020 |
Why?
|
| Gene Dosage | 1 | 2009 | 47 | 0.020 |
Why?
|
| Platelet Count | 1 | 2009 | 100 | 0.020 |
Why?
|
| Kidney Tubules, Proximal | 2 | 1994 | 81 | 0.020 |
Why?
|
| B-Cell Activation Factor Receptor | 1 | 2008 | 3 | 0.020 |
Why?
|
| Practice Guidelines as Topic | 1 | 2014 | 772 | 0.020 |
Why?
|
| Lymphocyte Count | 1 | 2008 | 53 | 0.020 |
Why?
|
| Species Specificity | 1 | 2009 | 302 | 0.020 |
Why?
|
| Vascular Cell Adhesion Molecule-1 | 1 | 2008 | 45 | 0.020 |
Why?
|
| E-Selectin | 1 | 2008 | 44 | 0.020 |
Why?
|
| Electrophoresis, Agar Gel | 1 | 1988 | 32 | 0.020 |
Why?
|
| Recurrence | 1 | 2011 | 948 | 0.020 |
Why?
|
| Autoradiography | 1 | 1988 | 94 | 0.020 |
Why?
|
| Staining and Labeling | 1 | 2008 | 144 | 0.020 |
Why?
|
| Gene Rearrangement, beta-Chain T-Cell Antigen Receptor | 1 | 1988 | 3 | 0.020 |
Why?
|
| Estradiol | 1 | 2009 | 176 | 0.020 |
Why?
|
| Deoxyribonucleases | 1 | 2007 | 8 | 0.020 |
Why?
|
| Isoelectric Point | 1 | 1987 | 9 | 0.020 |
Why?
|
| Terpenes | 1 | 2007 | 18 | 0.020 |
Why?
|
| Molecular Weight | 1 | 1988 | 358 | 0.020 |
Why?
|
| Administration, Oral | 1 | 2009 | 411 | 0.020 |
Why?
|
| Estrogens | 1 | 2009 | 173 | 0.020 |
Why?
|
| Polynucleotides | 2 | 1985 | 4 | 0.020 |
Why?
|
| Gamma Rays | 1 | 2007 | 64 | 0.020 |
Why?
|
| Histocompatibility Antigens Class II | 1 | 1988 | 77 | 0.020 |
Why?
|
| Phospholipids | 1 | 2007 | 108 | 0.020 |
Why?
|
| Rats, Inbred Strains | 2 | 1984 | 532 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2014 | 2004 | 0.020 |
Why?
|
| Antigens, Bacterial | 2 | 1999 | 54 | 0.020 |
Why?
|
| Lymphocytes | 1 | 2008 | 228 | 0.020 |
Why?
|
| Lung Neoplasms | 1 | 1996 | 1172 | 0.020 |
Why?
|
| Renal Artery Obstruction | 1 | 1987 | 29 | 0.020 |
Why?
|
| Hypertension, Renovascular | 1 | 1987 | 47 | 0.020 |
Why?
|
| Blood Platelets | 1 | 1988 | 284 | 0.020 |
Why?
|
| Cell Division | 1 | 1988 | 541 | 0.020 |
Why?
|
| Angiopoietin-1 | 1 | 2006 | 12 | 0.020 |
Why?
|
| Receptors, Complement 3b | 1 | 2006 | 35 | 0.020 |
Why?
|
| Renal Circulation | 1 | 1986 | 49 | 0.020 |
Why?
|
| Cell Lineage | 1 | 2006 | 146 | 0.020 |
Why?
|
| Specific Pathogen-Free Organisms | 1 | 2005 | 32 | 0.020 |
Why?
|
| Insulin Receptor Substrate Proteins | 1 | 2005 | 18 | 0.020 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 2006 | 52 | 0.020 |
Why?
|
| Monocytes | 1 | 2006 | 210 | 0.020 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 1 | 2005 | 32 | 0.020 |
Why?
|
| Cell Line, Transformed | 1 | 2005 | 100 | 0.020 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-1 | 1 | 2005 | 24 | 0.020 |
Why?
|
| Waldenstrom Macroglobulinemia | 1 | 1985 | 10 | 0.020 |
Why?
|
| Ligands | 2 | 1997 | 317 | 0.020 |
Why?
|
| Longitudinal Studies | 1 | 2009 | 1054 | 0.020 |
Why?
|
| Reference Values | 1 | 1986 | 579 | 0.020 |
Why?
|
| Chaperonin 60 | 2 | 1995 | 10 | 0.020 |
Why?
|
| Immunologic Factors | 1 | 2006 | 87 | 0.020 |
Why?
|
| Extracellular Matrix | 1 | 1989 | 493 | 0.020 |
Why?
|
| Anions | 1 | 1984 | 12 | 0.020 |
Why?
|
| Transmembrane Activator and CAML Interactor Protein | 1 | 2004 | 4 | 0.020 |
Why?
|
| Receptors, Tumor Necrosis Factor | 1 | 2004 | 32 | 0.020 |
Why?
|
| Cations | 1 | 1984 | 51 | 0.020 |
Why?
|
| Chromosomes, Artificial, Bacterial | 1 | 2004 | 8 | 0.020 |
Why?
|
| Nitric Oxide Synthase Type III | 1 | 2005 | 102 | 0.020 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2005 | 222 | 0.020 |
Why?
|
| Graft Rejection | 1 | 1988 | 458 | 0.020 |
Why?
|
| Immunoglobulins | 1 | 2004 | 97 | 0.020 |
Why?
|
| Tissue Distribution | 1 | 2004 | 282 | 0.020 |
Why?
|
| CD28 Antigens | 1 | 2003 | 12 | 0.010 |
Why?
|
| beta 2-Microglobulin | 1 | 2003 | 15 | 0.010 |
Why?
|
| Hematuria | 1 | 1983 | 24 | 0.010 |
Why?
|
| Life Expectancy | 1 | 2003 | 51 | 0.010 |
Why?
|
| Intercellular Adhesion Molecule-1 | 1 | 2003 | 52 | 0.010 |
Why?
|
| Lymphocyte Subsets | 1 | 2003 | 16 | 0.010 |
Why?
|
| CTLA-4 Antigen | 1 | 2003 | 45 | 0.010 |
Why?
|
| Haplotypes | 1 | 2003 | 174 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2005 | 331 | 0.010 |
Why?
|
| Antigens, Differentiation | 1 | 2003 | 49 | 0.010 |
Why?
|
| RNA, Messenger | 2 | 1998 | 1663 | 0.010 |
Why?
|
| Gene Rearrangement, B-Lymphocyte, Light Chain | 1 | 2002 | 2 | 0.010 |
Why?
|
| Immunoglobulin lambda-Chains | 1 | 2002 | 10 | 0.010 |
Why?
|
| Antigens, CD | 1 | 2003 | 230 | 0.010 |
Why?
|
| Drug Administration Schedule | 1 | 2003 | 567 | 0.010 |
Why?
|
| Th1 Cells | 1 | 2002 | 101 | 0.010 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 2002 | 204 | 0.010 |
Why?
|
| Bone Marrow Transplantation | 1 | 2002 | 149 | 0.010 |
Why?
|
| Gene Deletion | 1 | 2002 | 235 | 0.010 |
Why?
|
| Hypertension | 1 | 1991 | 1531 | 0.010 |
Why?
|
| Genotype | 1 | 2003 | 785 | 0.010 |
Why?
|
| Multigene Family | 2 | 1992 | 93 | 0.010 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2002 | 265 | 0.010 |
Why?
|
| Fas Ligand Protein | 1 | 2000 | 64 | 0.010 |
Why?
|
| Syk Kinase | 1 | 1999 | 10 | 0.010 |
Why?
|
| Graft vs Host Reaction | 1 | 1999 | 4 | 0.010 |
Why?
|
| Immunoglobulin D | 1 | 1999 | 14 | 0.010 |
Why?
|
| Enzyme Precursors | 1 | 1999 | 27 | 0.010 |
Why?
|
| Self Tolerance | 1 | 1999 | 8 | 0.010 |
Why?
|
| COS Cells | 1 | 2000 | 155 | 0.010 |
Why?
|
| Muramidase | 1 | 1999 | 38 | 0.010 |
Why?
|
| Helper Viruses | 1 | 1999 | 2 | 0.010 |
Why?
|
| Housing, Animal | 1 | 1999 | 16 | 0.010 |
Why?
|
| Heart | 1 | 2004 | 850 | 0.010 |
Why?
|
| Capsid Proteins | 1 | 1999 | 27 | 0.010 |
Why?
|
| Single-Blind Method | 1 | 2000 | 249 | 0.010 |
Why?
|
| Immunologic Memory | 1 | 1999 | 75 | 0.010 |
Why?
|
| Cellular Senescence | 1 | 2000 | 112 | 0.010 |
Why?
|
| Lymphocyte Transfusion | 1 | 1998 | 4 | 0.010 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 1999 | 195 | 0.010 |
Why?
|
| Organ Size | 1 | 1999 | 242 | 0.010 |
Why?
|
| Antibodies, Viral | 1 | 1999 | 110 | 0.010 |
Why?
|
| Basic Helix-Loop-Helix Leucine Zipper Transcription Factors | 1 | 1998 | 24 | 0.010 |
Why?
|
| Hepatocyte Nuclear Factor 4 | 1 | 1998 | 28 | 0.010 |
Why?
|
| Viral Vaccines | 1 | 1998 | 17 | 0.010 |
Why?
|
| Early Growth Response Protein 1 | 1 | 1998 | 42 | 0.010 |
Why?
|
| Retroviridae | 1 | 1998 | 29 | 0.010 |
Why?
|
| Cholesterol, HDL | 1 | 1998 | 112 | 0.010 |
Why?
|
| Brain | 1 | 1989 | 2175 | 0.010 |
Why?
|
| Autopsy | 1 | 1997 | 56 | 0.010 |
Why?
|
| Lymph Nodes | 1 | 1999 | 258 | 0.010 |
Why?
|
| Cancer Vaccines | 1 | 1998 | 61 | 0.010 |
Why?
|
| Fatal Outcome | 1 | 1997 | 164 | 0.010 |
Why?
|
| Lymphoid Tissue | 1 | 1996 | 30 | 0.010 |
Why?
|
| Renal Dialysis | 1 | 1997 | 174 | 0.010 |
Why?
|
| Hypergammaglobulinemia | 1 | 1996 | 2 | 0.010 |
Why?
|
| Vaccination | 1 | 1998 | 182 | 0.010 |
Why?
|
| Promoter Regions, Genetic | 1 | 1998 | 614 | 0.010 |
Why?
|
| Diagnostic Errors | 1 | 1996 | 100 | 0.010 |
Why?
|
| Diet | 1 | 1999 | 513 | 0.010 |
Why?
|
| Skin Diseases | 1 | 1997 | 122 | 0.010 |
Why?
|
| Cadmium Chloride | 1 | 1994 | 3 | 0.010 |
Why?
|
| Mycobacterium bovis | 1 | 1994 | 3 | 0.010 |
Why?
|
| HSP90 Heat-Shock Proteins | 1 | 1995 | 46 | 0.010 |
Why?
|
| Cadmium | 1 | 1994 | 21 | 0.010 |
Why?
|
| Cytotoxicity, Immunologic | 1 | 1994 | 66 | 0.010 |
Why?
|
| Chlorides | 1 | 1994 | 68 | 0.010 |
Why?
|
| CD3 Complex | 1 | 1994 | 35 | 0.010 |
Why?
|
| Precipitin Tests | 1 | 1994 | 88 | 0.010 |
Why?
|
| Matrix Metalloproteinase 1 | 1 | 1994 | 74 | 0.010 |
Why?
|
| Creatinine | 1 | 1995 | 243 | 0.010 |
Why?
|
| Histones | 1 | 1995 | 111 | 0.010 |
Why?
|
| Liver | 1 | 1998 | 1118 | 0.010 |
Why?
|
| Germ Cells | 1 | 1992 | 17 | 0.010 |
Why?
|
| Peptide Fragments | 1 | 1994 | 483 | 0.010 |
Why?
|
| Hematocrit | 1 | 1991 | 70 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 1995 | 3256 | 0.000 |
Why?
|
| Pulse | 1 | 1987 | 23 | 0.000 |
Why?
|
| Antipsychotic Agents | 1 | 1989 | 247 | 0.000 |
Why?
|
| Aldosterone | 1 | 1987 | 51 | 0.000 |
Why?
|
| Renin | 1 | 1987 | 96 | 0.000 |
Why?
|
| Macroglobulins | 1 | 1985 | 3 | 0.000 |
Why?
|
| Immunochemistry | 1 | 1985 | 17 | 0.000 |
Why?
|
| Klebsiella pneumoniae | 1 | 1985 | 18 | 0.000 |
Why?
|
| Aged, 80 and over | 1 | 1995 | 4843 | 0.000 |
Why?
|
| Immunoglobulin Allotypes | 1 | 1985 | 82 | 0.000 |
Why?
|
| Antibodies, Bacterial | 1 | 1985 | 90 | 0.000 |
Why?
|
| Antigens, Heterophile | 1 | 1983 | 1 | 0.000 |
Why?
|
| Antibodies, Heterophile | 1 | 1983 | 11 | 0.000 |
Why?
|
| Arthritis, Rheumatoid | 1 | 1984 | 155 | 0.000 |
Why?
|
| Complement Pathway, Alternative | 1 | 1983 | 69 | 0.000 |
Why?
|
| Phagocytes | 1 | 1982 | 15 | 0.000 |
Why?
|
| Leukocytes | 1 | 1982 | 99 | 0.000 |
Why?
|
| Blood Pressure | 1 | 1987 | 1447 | 0.000 |
Why?
|
| Retrospective Studies | 1 | 1991 | 7264 | 0.000 |
Why?
|